Semaglutide improves contractile function in human atrial myocardium of patients with heart failure and preserved ejection fraction

Key Result

Semaglutide improves contractile function in human atrial myocardium of patients with heart failure and preserved ejection fraction.

Key Points

• This research aims to evaluate the effects of semaglutide on contractile function in the atrial myocardium of patients with heart failure and preserved ejection fraction.
• Investigated higher treatment doses of semaglutide in obese patients with heart failure and preserved ejection fraction.
• Part of the STEP-HFpEF programme focusing on cardiac function.
• Evaluated contractile function in atrial myocardium.
• Semaglutide treatment resulted in significant improvements in contractile function of atrial myocardium.
• Findings suggest potential benefits for heart failure management in patients with obesity.